International Immunopharmacology, Journal Year: 2024, Volume and Issue: 138, P. 112571 - 112571
Published: June 28, 2024
Language: Английский
Drug Resistance Updates, Journal Year: 2024, Volume and Issue: 73, P. 101042 - 101042
Published: Jan. 4, 2024
Drug resistance in cancer remains a major challenge oncology, impeding the effectiveness of various treatment modalities. The nuclear factor-kappa B (NF-κB) signaling pathway has emerged as critical player development drug cells. This comprehensive review explores intricate relationship between NF-κB and cancer. We delve into molecular mechanisms through which activation contributes to against chemotherapeutic agents, targeted therapies, immunotherapies. Additionally, we discuss potential strategies overcome this by targeting signaling, such small molecule inhibitors combination therapies. Understanding multifaceted interactions is crucial for more effective strategies. By dissecting complex network NF-κB, hope shed light on novel therapeutic approaches that can enhance outcomes, ultimately improving prognosis patients. aims provide overview current state knowledge its role resistance, offering insights may guide future research interventions fight
Language: Английский
Citations
37
Cancer Drug Resistance, Journal Year: 2024, Volume and Issue: unknown
Published: March 13, 2024
Aim: Circular RNAs (circRNAs) have been found to be involved in tumor progression, but their role colorectal cancer (CRC) immune escape remains elucidated. Methods: circRNAs differentially expressed responsive and resistant CRC tissues programmed cell death 1 (PD-1) antibody therapy were identified by microarray analysis. The clinical pathological significance of circNCOA3 was validated a separate cohort samples. function explored experimentally. RNA immunoprecipitation luciferase activity assays conducted identify downstream targets circNCOA3. Results: markedly overexpressed samples PD-1 blockade. expression significantly correlated with adverse phenotypes poor outcomes patients. Knockdown suppressed the proliferative invasive capability cells. Moreover, knockdown increased proportion CD8+ T cells while decreasing myeloid-derived suppressor (MDSCs). inhibited growth sensitivity treatment mouse models. Further studies revealed that acted as competing endogenous (ceRNA) for miR-203a-3p.1 influence level CXCL1. Conclusion: Our findings indicate might useful potential biomarker predict efficacy prognosis patients treated anti-PD-1 therapy.
Language: Английский
Citations
6
Journal of Extracellular Vesicles, Journal Year: 2024, Volume and Issue: 13(7)
Published: July 1, 2024
Abstract Head and neck squamous cell carcinoma (HNSCC) is a global cancer burden with 5‐year overall survival rate of around 50%, stagnant for decades. A tumour‐induced immunosuppressive microenvironment contributes to HNSCC progression, the adenosine (ADO) pathway an upregulated expression inhibitory immune checkpoint regulators playing key role in this context. The correlation between high neutrophil‐to‐lymphocyte ratio (NLR) advanced tumour staging suggests involvement neutrophils (NØ) progression. Interestingly, we associated NLR increased intracellular PD‐L1 localization primary samples, potentially mediating more aggressive characteristics therefore synergistically favouring Still, further research needed harness knowledge effective treatments overcome resistance. Since it hypothesized that (TME) may be influenced by small extracellular vesicles (sEVs) secreted tumours (TEX), study aims investigate impact HNSCC‐derived TEX on NØ blockade ADO receptors as potential strategy reverse pro‐tumour phenotype NØ. UMSCC47‐TEX exhibited CD73 enzymatic activity involved signalling, well inhibitor PD‐L1. Data revealed induce chemotaxis sustained interaction promotes shift into phenotype, dependent (P1R), increasing CD170 subpopulation, expression, followed secretome. Blocking A3R reduced expression. Co‐culture experiments cells demonstrated TEX‐modulated increase CD73/PD‐L1 axis, through Cyclin D‐CDK4/6 signalling. To support these findings, CAM model was treated supernatant. Moreover, promoted migration, invasion, death. Targeting P1R NØ, particularly A3R, therapeutic counteract immunosuppression HNSCC. Understanding TEX‐mediated crosstalk offers insights immunomodulation improving therapies.
Language: Английский
Citations
5
APOPTOSIS, Journal Year: 2025, Volume and Issue: unknown
Published: April 11, 2025
Language: Английский
Citations
0
Cytokine, Journal Year: 2024, Volume and Issue: 177, P. 156561 - 156561
Published: March 2, 2024
Language: Английский
Citations
3
hLife, Journal Year: 2024, Volume and Issue: 2(8), P. 380 - 396
Published: June 9, 2024
Chimeric antigen receptor (CAR)-T cell therapy has made remarkable breakthroughs in treating cancers, especially hematologic malignancies, yet its broader application cancer treatment is hindered by multiple challenges. Meanwhile, the development of Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) and derived technologies provided unprecedentedly efficient tools for genomic cellular reprogramming, offering potential advantages developing CAR-T therapy. There hence a rapidly increasing interest applying CRISPR to engineer cells. Here, we present review recent research utilizing boost enhancing safety or effectiveness. We first provide an overview technology, followed discussions on how related can be adopted tackle various issues associated with therapy, either via knockout/knockin specific genes CRISPR-based screening. also summarize clinical trials involving CRISPR-edited Lastly, address risks engineering.
Language: Английский
Citations
3
Cancer Letters, Journal Year: 2024, Volume and Issue: 597, P. 217072 - 217072
Published: June 15, 2024
CD39 is a pivotal enzyme in cancer, regulating immune response and tumor progression via extracellular ATP adenosine the microenvironment (TME). Beyond its established immunoregulatory function, influences cancer cell angiogenesis metabolism, opening new frontiers for therapeutic interventions. Current research faces gaps understanding CD39's full impact across types, with ongoing debates about potential beyond modulating evasion. This review distills multifaceted roles, examining dual actions implications prognosis treatment. We analyze latest strategies, highlighting need an integrated approach that combines molecular insights TME dynamics to innovate care. synthesis underscores integral role, charting course precision oncology seeks unravel controversies harness promise improved outcomes.
Language: Английский
Citations
3
Journal of Experimental & Clinical Cancer Research, Journal Year: 2025, Volume and Issue: 44(1)
Published: March 11, 2025
Abstract Background In-depth exploration into the dysregulation of lipid metabolism in hepatocellular carcinoma (HCC) has contributed to development advanced antitumor strategies. CRSP8 is a critical component mediator multiprotein complex involved transcriptional recruiting. However, regulatory mechanisms on fatty acid reprogramming and HCC progression remain unclear. Methods In-silico/house dataset analysis, droplets (LDs) formation, mouse models targeted lipidomic analysis were performed determine function regulating HCC. The subcellular colocalization live cell imaging LDs, transmission electron microscopy, co-immunoprecipitation luciferase reporter assay employed investigate their potential mechanism. Results was identified as highly expressed oncogene essential for proliferation aggressiveness vitro vivo. tumor promotion accompanied by LDs accumulation increased de novo acids (FAs) synthesis. Moreover, diminished between LC3 impair lipophagy nuclear-localized PPARα-dependent manner, which decreased mobilization FAs from degradation hindered mitochondrial oxidation. Mechanistically, small ras family GTPase RAN transcriptionally activated , leading reinforcement RAN/CRM1-mediated nuclear export. CRSP8-induced enhanced formation RAN/CRM1/PPARα nucleus-cytoplasm shuttling heterotrimer orchestrated cytoplasmic translocation PPARα, attenuated nPPARα-mediated catabolism, subsequently exacerbated progression. In CRSP8-enriched HCC, synthesis inhibitor Orlistat effectively reshaped immunosuppressive microenvironment (TME) improved efficacy anti-PD-L1 therapy Conclusion Our study establishes that CRSP8-driven facilitates via impaired lipophagy-derived catabolism. Targeting energy supply sourced lipids could represent promising therapeutic strategy treating CRSP8-sufficient
Language: Английский
Citations
0
Frontiers in Pharmacology, Journal Year: 2024, Volume and Issue: 15
Published: July 19, 2024
Recent studies have revealed that sarcopenia can adversely affect the efficacy of PD-1 inhibitors in treatment non-small cell lung cancer (NSCLC). are immune checkpoint widely used various cancers. However, NSCLC patients may poorer outcomes when receiving inhibitor treatment, and through metabolic mechanisms. In this article, we summarize reported negative impact on effectiveness recent years. Based existing research results, analyze possible mechanisms by which affects discuss strategies to address issue. This could help understand provide more accurate expectations for clinicians patients. Additionally, present tailored intervention sarcopenic undergoing therapy, aiming optimize enhance patient quality life. Nevertheless, further is warranted elucidate impacts identify efficacious approaches improving
Language: Английский
Citations
2
International Immunopharmacology, Journal Year: 2024, Volume and Issue: 138, P. 112571 - 112571
Published: June 28, 2024
Language: Английский
Citations
0